The Evolution of Genomics Dealmaking
SmithKline's 1993 $125 million alliance with Human Genome Sciences looked enormously overpriced at the time-and then quickly began to look more reasonable as prices for genomics deals skyrocketed. It was only with the addition of Takeda as a partnerthat the true possibilities of the SB/HGS alliance became evident: if both companies were to market the HGS database to partners, both could benefit.
You may also be interested in...
Pain relief product sales grew 27% and upper respiratory sales 35% for the week ended 7 March as consumers respond to COVID-19, according to Nielsen data noted in a Jefferies report on consumer health purchasing trends. Private label market share is up slightly, while OTC purchases continue primarily in conventional stores.
Managing partner Corey Goodman said venBio didn’t have trouble closing its fund, because the venture capital firm prepared its investors for an economic downturn months ago.
The US FDA has proposed moving two categories of hepatitis C diagnostics to class II from class III because they pose relatively low risk.